Fetal growth charts for diverse Asian and Oceania cohorts

Fetal growth charts compare estimated fetal weight, length and later birth weight with reference ranges for gestational age. They help clinicians identify small- or large-for-gestational-age patterns, but a percentile is not a diagnosis. The central question for Asian and Oceania populations is whether a population-based reference or a customised model better represents fetal growth when maternal, placental and demographic factors differ from the chart’s source population. Learn more about リウマチ患者の脂質異常症 糖尿病 高血圧の包括的マネジメント.

Asian cohorts are not one homogeneous group. Chinese, Japanese, Korean, South and Southeast Asian populations differ in body composition, nutrition, parity, disease patterns and access to assisted reproductive technology. Australia adds further variation, including Asian-born families in Sydney, Melbourne, Brisbane and Perth, and Aboriginal and Torres Strait Islander communities for whom inequitable care and limited local services can affect the measurement trail.

Population-based charts describe outcomes observed in a defined cohort; customised charts estimate an individual fetus’s growth using maternal and pregnancy variables. Neither removes bias, and poor data linkage can make either look precise. Chart selection therefore belongs within a wider pathway of ultrasound dating, repeat growth assessment, blood pressure and laboratory review, and clinical examination.

Perinatal research networks across Asia and Oceania make this more than a local statistical choice. The FAOPS 2020 scientific programme was designed to connect clinicians around fetal growth, neonatal outcomes and related perinatal science. Although the congress was cancelled in April 2020, its regional focus remains relevant to harmonising definitions, testing models and evaluating outcomes across different health systems.

Population and customised chart approaches

A population-based chart ranks fetal size against a reference group, often stratified by gestational age and sex. Such charts are relatively simple to implement and can be excellent where the local population resembles the source data. Their weakness is misclassification when the reference cohort has different maternal characteristics, preterm birth rates or obstetric practices. A customised model adjusts expected growth for variables such as parity, maternal height or body mass index, diabetes, hypertension and assisted reproduction.

Decision feature Population-based chart Customised chart
Reference Fixed cohort and gestational-age pattern Individual pregnancy and selected maternal or fetal variables
Main strength Transparent, consistent and easy to apply May reduce non-biological variation when variables and calibration are sound
Main caution Outdated or unrepresentative cohorts can misclassify growth Missing inputs, poorly validated coefficients and software dependence can introduce error
Asian cohort role Useful if local outcomes are represented and performance is audited Useful when tested across relevant Asian and Oceania populations
Operational need Clear centile definitions and local surveillance pathways Governance, data quality, version control and subgroup monitoring

Neither approach is universally superior. A well-constructed population chart may outperform a weak customisation model, especially if the latter omits important predictors or was developed in a population unlike the mother and fetus. Validation should examine calibration across gestational ages and subgroups, not merely whether more infants avoid a low-percentile label. Centres should also compare the chart with their own recent outcomes.

Regional conference archives can help teams trace methodological discussions; the Changwon 2018 meeting is one such reference point. Whatever chart is selected, version control matters: changing the reference population can shift centiles and alter referral thresholds without any biological change in fetal size.

What Asian cohort data can reveal

Large Asian datasets have clarified associations between fetal growth, maternal metabolism and placental dysfunction. Japanese, Korean and Chinese studies have explored customised expected growth, while Singaporean and other regional cohorts have contributed data on birth weight, assisted reproduction and hypertensive disorders. INTERGROWTH-21st and WHO standards offer international benchmarks with distinct scopes and limitations. These datasets support subgroup-specific investigation, but a coefficient derived in one country should be tested elsewhere before routine use.

Regional collaboration was the stated purpose of the FAOPS 2020 congress, planned for Tokyo in conjunction with PREBIC AA 2020. COVID-19 and associated international travel difficulties led to cancellation in April 2020, yet the scientific programme remains relevant to the need for shared protocols and difficult cases across borders. For chart research, regional collaboration can mean common definitions for small-for-gestational-age, abnormal growth velocity, pre-eclampsia and maternal diabetes, allowing centres to compare findings without counting incompatible labels as equivalent.

Important signals include growth deceleration on serial ultrasound, a persistently low estimated fetal weight, and discordance between abdominal circumference and other biometric measures. Customisation may be especially relevant after assisted reproductive technology or in pregnancies complicated by diabetes or hypertension. It should not be used to dismiss persistent abnormal growth: severe growth restriction, abnormal Dopplers or maternal pre-eclampsia still require urgent assessment.

Applying the evidence in Australian maternity care

Australian maternity care is delivered through public hospitals, private obstetric services and shared-care arrangements involving general practitioners and midwives. In Sydney and Melbourne, tertiary obstetric units often have access to fetal medicine and advanced ultrasound; in regional and remote areas, travel for serial scans may be difficult. Chart choice should therefore be paired with a practical plan for reliable dating, repeated measurements and escalation.

Everyday access shapes the evidence base. Many pregnant patients first confirm pregnancy through a general practitioner, then receive public or private ultrasound through a local or metropolitan service. The Australian market includes widely available obstetric ultrasound as well as Medicare-supported public care, and some families use private health insurance for additional appointments. These pathways can create differences in scan timing, equipment, operator technique and attendance at follow-up, all of which influence growth velocity data.

Material on peripartum cardiomyopathy care shows how perinatal conditions can overlap and why chart interpretation needs the wider clinical picture. A low-growth pattern may reflect placental compromise, maternal illness, congenital conditions or measurement error. Australian teams should record chart type and version, estimated fetal weight, gestational age, clinical risk factors and the plan for reassessment so that apparently small centile differences do not trigger inconsistent decisions.

Interpretation, equity and clinical governance

Equity begins with data quality. Race and ancestry are not reliable substitutes for direct physiological measures. Some customised models include ethnicity because it captures unmeasured environmental or population effects; others avoid it to reduce discrimination. Asian families should not be assigned a chart solely from a surname or appearance, and Aboriginal and Torres Strait Islander patients need charts validated with appropriate local outcome data.

Privacy and transparency are essential when models use linked pregnancy records. Under the Privacy Act 1988 and the Australian Privacy Principles, services should limit collection, define access, and explain how de-identified data support quality improvement. Health-service identifiers and state health-records legislation add further operational duties. Model governance should include documented approval, version control, subgroup performance monitoring and a route to report charts that misclassify families.

Clinical interpretation also benefits from shared education on associated risks. International material on comprehensive risk management demonstrates the broader value of connecting metabolic, cardiovascular and obstetric factors. A fetal-growth committee can use such frameworks to align surveillance for diabetes, hypertension, dyslipidaemia and fetal abnormalities, while keeping decisions centred on the individual pregnancy rather than a percentile alone.

A practical pathway for clinics and research teams

Start by defining the purpose of the chart: screening for fetal growth restriction, detecting large-for-gestational-age risk, supporting birth planning or contributing to research. Audit the population served, gestational-age accuracy, missing maternal variables and current practice before changing systems. Where local Asian cohort data are inadequate, use a validated reference with transparent limits and preserve the ability to audit outcomes.

For individual cases, clinicians can combine a consistent chart with serial ultrasound, maternal history, blood pressure, laboratory results and blood-flow assessment. Repeat measurements with the same technique where possible, avoid making a single scan decisive, and escalate when growth falls, Dopplers are abnormal or pre-eclampsia develops. A customised model should be used only if its inputs are available and its performance is credible for the mother and fetus.

Research teams can now create a shared protocol that compares population-based and customised charts across Australian Asian cohorts, links findings with perinatal outcomes and publishes subgroup performance. The first action for hospital leaders, midwives, obstetricians and ultrasound providers is to nominate a clinical lead, agree on chart governance and audit one year of growth classifications. That coordinated step can give families a more consistent fetal growth pathway.